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HER2/c-erb B-2 is the homologue of the rat proto-oncogene neu
(Schecter et al, 1984) and is located on chromosome 17q21
(Coussens et al, 1985; Fukushige et al, 1986). It encodes a
185-kDa transmembrane glycoprotein receptor (p185HER2) that
has intrinsic tyrosine kinase activity (Maguire et al, 1989). An
anti-HER2 monoclonal antibody, rhumAbHER2 (trastuzumab), is
a humanized form of the murine 4D5 antibody which is directed
to the external domain of HER2 and inhibits the growth of cells
overexpressing HER2 (Carter et al, 1992; Tokuda et al, 1996;
Baselga et al, 1998). Recently, clinical phase studies with
rhumAbHER2 as a single agent were conducted in patients with
metastatic breast cancer overexpressing HER2, and 12 and 15%
response rates were reported (Baselga et al, 1996; Cobleigh et al,
1998). In addition, two clinical studies with chemotherapy
combined with rhumAbHER2 were conducted and demonstrated
that the addition of rhumAbHER2 to chemotherapy significantly
increased not only the response rate but also the duration of
response (Pegram et al, 1998; Slamon et al, 1998). Very recently,
this antibody has been approved for clinical use with patients
having HER2-overexpressing breast cancer in the United States.
It has been reported that either amplification of the HER2 proto-
oncogene or overexpression of HER2 has been observed in
25–30% of primary breast cancers and has correlated with a poor
prognosis (Slamon et al, 1987; Wright et al, 1989). Approximately
half of these cancers were oestrogen receptor (ER)-positive
(McCann et al, 1991). It has been also suggested that, in the
adjuvant setting, an anti-oestrogen, tamoxifen, may worsen
disease-free survival of patients with breast cancer expressing
both ER and HER2 (Bianco et al, 1998).
Anti-oestrogens are well known to be effective for the treatment
of ER-positive breast carcinomas. Unfortunately, however, most
of them eventually develop resistance to anti-oestrogens. It is also
known that anti-oestrogens are less effective for the treatment of
patients with breast cancer overexpressing HER1 or HER2
together with ER (Ross and Fletcher, 1998). Previous experiments
have indicated that oestrogen down-regulates HER2 in ER-posi-
tive breast cancer cells and anti-oestrogen reverses the oestrogen-
induced decrease in HER2 expression (Read et al, 1990). Thus, it
is conceivable that anti-oestrogen may activate a HER2-signalling
pathway and may cause resistance to anti-oestrogen. If so, it seems
reasonable to use both anti-oestrogen and anti-HER2 antibody for
the treatment of patients with breast cancer expressing both ER
and HER2.
In the present study, we investigated the effects of combined
treatment with a steroidal, pure anti-oestrogen, ICI 182,780, and a
humanized anti-HER2 monoclonal antibody, rhumAbHER2, in
three breast cancer cell lines which respectively express different
levels of ER and HER2 to explore the possible additive effect of
the combined treatment.
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Summary Anti-oestrogen is effective for the treatment of oestrogen receptor (ER)-positive breast carcinomas, but most of these tumours
become resistant to anti-oestrogen. It has been suggested that anti-oestrogen therapy may induce a HER2 signalling pathway in breast
cancer cells and this may cause resistance to anti-oestrogen. Thus, it is conceivable that combined therapy with anti-oestrogen and anti-
HER2 antibody might be more effective. In the present study, we investigated the effect of combined treatment with a humanized anti-HER2
monoclonal antibody, rhumAbHER2 (trastuzumab), and an anti-oestrogen, ICI 182,780, on the cell growth of three human breast cancer cell
lines which respectively express different levels of ER and HER2. The combined treatment enhanced the growth inhibitory effect on ML-20
cells, which express a high level of ER and a moderate level of HER2, but showed no additive effect on either KPL-4 cells, which express no
ER and a moderate level of HER2, or MDA-MB-231 cells, which express no ER and a low level of HER2. It is also suggested that both the
antibody and anti-oestrogen induce a G1–S blockade and apoptosis. These findings indicate that combined treatment with anti-HER2
antibody and anti-oestrogen may be useful for the treatment of patients with breast cancer expressing both ER and HER2. © 2000 Cancer
Research Campaign
Keywords: anti-HER2 antibody; anti-oestrogen; breast cancer; additive effect; apoptosis
46
British Journal of Cancer (2000) 82(1), 46–51
© 2000 Cancer Research Campaign
Article no. bjoc.1999.0875
Received 12 April 1999
Revised 21 June 1999
Accepted 22 June 1999
Correspondence to: J KurebayashiAdditive effect of rhuMAbHER2 and ICI 182,780 47
British Journal of Cancer (2000) 82(1), 46–51 © 2000 Cancer Research Campaign
MATERIALS AND METHODS
Human breast cancer cell lines
The ML-20 cell line is a transfectant of the MCF-7 cell line with
the pCHC b-Gal expression vector encoding the bacterial lacZ
gene (Kurebayashi et al, 1993). The MDA-MB-231 cell line was
kindly provided by Dr Robert B Dickson (Lombardi Cancer
Center, Georgetown University Medical Center, Washington, DC,
USA). The KPL-4 cell line was established in our laboratory and
its characterization has been published elsewhere (Kurebayashi et
al, 1999). This cell line was derived from the malignant pleural
effusion of a Japanese patient with recurrent breast cancer. All of
the cell lines were routinely cultured in Dulbecco’s modified
Eagle’s medium (DMEM; ICN Biochemicals, Costa Mesa, CA,
USA) supplemented with 5% fetal bovine serum (FBS; ICN
Biochemicals Japan, Osaka, Japan).
Reagents
The steroidal, pure anti-oestrogen, ICI 182,780, was kindly
provided by Zeneca Pharmaceuticals (Macclesfield, UK). ICI
182,780 was dissolved with 100% ethanol and added to the
medium at a final ethanol concentration of 0.1%. The humanized
anti-ErbB-2 monoclonal antibody, rhumAbHER2, was kindly
provided by Mitsubishi Chemical Co. (Tokyo, Japan).
ER analysis
Oestrogen receptor (ER) levels in the cell pellet of the three cell
lines were measured by an enzyme immunoassay using ER-EIA
kits (Dinabot, Tokyo, Japan) following the manufacturer’s recom-
mendation.
Flow cytometric analysis of HER family member
expression
Approximately 1 ´ 106 cells per sample were harvested with
trypsin, stained with first antibodies for 1 h and washed with phos-
phate-buffered saline (PBS) twice. Then they were stained with
secondary fluoroscein isothiocyanate (FITC)-antimouse antibody
(Becton Dickinson, San Jose, CA, USA) for 30 min and washed
with PBS twice. The level of each HER family member was
analysed by a flow cytometer (Becton Dickinson). The first anti-
bodies were: anti-HER1 monoclonal antibody (Oncogene Science,
Uniondale, NY, USA), anti-HER2 monoclonal antibody (Ab-2,
NeoMarker, Freemont, CA, USA), anti-HER3 monoclonal anti-
body (NeoMarker) and anti-HER4 monoclonal antibody
(NeoMarker). The level of each HER family member was
expressed as the product of the specific peak fluorescence inten-
sity divided by the background peak intensity (Kurebayashi et al,
1999).
Cell growth in vitro
Three cell lines were respectively plated at a density of 5 ´ 104
cells per well in 12-well plates (SB Medical, Tokyo, Japan) and
grown in DMEM supplemented with 5% fetal bovine serum
(FBS) at 37°C in a 5% carbon dioxide atmosphere for 2 days. The
cells were then washed with PBS and incubated with phenol red-
free RPMI-1640 medium (Gibco-BRL, Bethesda, MD, USA)
supplemented with 2% dextran-coated charcoal-stripped FBS
(Kurebayashi et al, 1998) plus 10–9–10–7 M ICI 182,780, 0.1–
10 mg ml–1 rhumAbHER2 or 10–7 M ICI 182,780 and/or 10 mg ml–1
of rhumAbHER2. The culture medium was changed every other
day. Triplicate wells were trypsinized 4 days after switching the
culture medium and the cell number was counted with a Coulter
counter (Coulter Electronics, Harpenden, UK).
Cell cycle analysis
Three cell lines were plated at a density of 5 ´ 104 cells per well in
12-well plates and grown in DMEM supplemented with 5% FBS
for 3 days. Then the cells were washed with PBS and treated with
phenol red-free RPMI-1640 medium supplemented with 2%
dextran-coated charcoal-stripped FBS plus 10–7 M ICI 182,780,
10 mg ml–1 rhumAbHER2 or both. Triplicate wells were
trypsinized, harvested a day after and stained with propidium
iodide using the CycleTest Plus DNA Reagent Kit (Becton
Dickinson). Flow cytometry was performed with a FACSort flow
cytometer (Becton Dickinson), and the DNA histogram was
analysed by a CELLQuest Version 1.2.2 (Becton Dickinson).
Detection of apoptosis by flow cytometry
The ML-20 and KPL-4 cell lines were plated at a density of 4 ´ 105
cells per well in 6-well plates (SB Medical, Tokyo, Japan) and
grown in DMEM supplemented with 5% FBS for 2 days. Then the
cells were washed with PBS and treated with phenol red-free
RPMI-1640 medium supplemented with 2% dextran-coated
charcoal-stripped FBS plus 10–7 M ICI 182,780, 10 mg ml–1
rhumAbHER2 or both. Duplicated wells were trypsinized and
harvested 3 days after. The percentages of apoptotic cells were
measured with a FACSCaliber flow cytometer (Becton Dickinson
Immunocytometry Systems, Mansfield, MA, USA) using an in
situ cell death detection kit (Boehringer Mannheim, Germany)
according to the manufacturer’s recommendations as described
elsewhere (Otsuki et al, 1998).
Detection of apoptosis by immunocytochemistry
The ML-20 and KPL-4 cell lines were plated at a density of 1 ´ 106
cells in T-75 flasks (Corning Japan, Tokyo, Japan) and grown in
DMEM supplemented with 5% FBS for 3 days. Then the cells
were washed with PBS and treated with phenol red-free RPMI-
1640 medium supplemented with 2% dextran-coated charcoal-
stripped FBS plus 10–7 M ICI 182,780, 10 mg ml–1 rhumAbHER2
or both. Duplicated flasks were trypsinized and harvested 2 days
after. The cell pellets were fixed with 5% buffered-formalin and
embedded in paraffin. DNA breaks in the sections were detected
by nick end labelling using an ApopTag in situ apoptosis detection
kit (Oncor Inc., Gaithersburg, MD, USA) as described elsewhere
(Kuwashima et al, 1996). The areas of most intense staining were
identified in each sample, and approximately 500 cells per sample
were examined. The percentage of cells showing positive staining
was calculated in each sample.
Statistical analysis
ER content, percentages of control cell numbers, percentages of
the S phase or G0/G1 phase of the cell cycle and percentages of
apoptotic cells were expressed as means ± s.e.m. These values for48 H Kunisue et al
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the control and treated groups were compared using analysis of
variance (ANOVA) with StatView computer software (ATMS Co.,
Tokyo, Japan). All the experiments in this study were repeated at
least twice and the reproducibility of the results was confirmed.
RESULTS
ER levels and HER family member expression
The ML-20 cells expressed a high level of ER (112 ± 9.9 fmol
mg–1 protein) but neither the KPL-4 cells nor the MDA-MB-231
cells expressed a detectable level of ER (the limit of detection of
the ER assay was 5.0 fmol mg–1 protein).
Flow cytometric analysis showed that both the ML-20 cells and
the KPL-4 cells expressed a moderate level of HER2 and HER3
and a low level of HER1 and HER4. The MDA-MB-231 cells
expressed a low level of HER2, HER3 and HER4 and a high level
of HER1 (Table 1).
Growth inhibitory effect of ICI 182,780, rhumAbHER2 or
their combination
Both ICI 182,780 (10–9–10–7 M) alone and rhumAbHER2 (0.1–
10 mg ml–1) alone dose-dependently inhibited the growth of ML-20
cells (Figure 1 A, B). The inhibition rates were 0.40 for 10–7 M ICI
182,780 (P = 0.0008 in comparison with the control) and 0.20 for
10 mg ml–1 rhumAbHER2 (P = 0.0094). rhumAbHER2 (0.1–
10 mg ml–1) also dose-dependently inhibited the growth of KPL-4
cells (Figure 1C). The inhibition rate was 0.14 for 10 mg ml–1
rhumAbHER2 (P = 0.0021). No growth inhibitory effect of ICI
182,780 was observed in either KPL-4 or MDA-MB-231 cells.
rhumAbHER2 showed no effect on the MDA-MB-231 cell growth
(data not shown).
To investigate a possible additive effect of rhumAbHER2 and
ICI 182,780, 10 mg ml–1 rhumAbHER2 and 10–7 M ICI 182,780
were concomitantly administered. The combined treatment inhib-
ited the growth of ML-20 cells more than the respective agent
alone (Figure 2A). The inhibition rates were 0.36 for 10–7 M ICI
182,780, 0.21 for 10 mg ml–1 rhumAbHER2 and 0.55 for their
combination. In contrast, no additive effect was observed in KPL-
4 and MDA-MB-231 cells (Figure 2 B, C).
Effects of ICI 182,780 and rhumAbHER2 on cell cycle
progression and apoptosis
Both ICI 182,780 (10–7 M) alone and rhumAbHER2 (10 mg ml–1)
alone significantly increased the percentage of the G0/G1 phase
(P = 0.0001 and P = 0.01 respectively, in comparison with the
control) and decreased the percentage of S phase (P = 0.0001 and
P = 0.0015 respectively) in ML-20 cells. In addition, the combined
treatment promoted the G1–S blockade more than the respective
agent alone (Table 2). In KPL-4 cells, on the other hand,
rhumAbHER2 tended to increase the percentage of G0/G1 phase
(P = 0.39) and decrease the percentage of S phase (P = 0.12),
but no additive effect of the combined treatment was observed
(Table 2).
Both ICI 182,780 (10–7 M) alone and rhumAbHER2 (10 mg ml–1)
alone also induced apoptosis in the ML-20 cell line. In the flow
cytometric analysis, ICI 182,780 alone or rhumAbHER2 alone
tended to increase the percentage of TUNEL-positive cells but a
Table 1 Comparison of expression levels of HER family members in three
human breast cancer cell lines
ML-20 KPL-4 MDA-MB-231
HER1 2 2 55
HER2 14 13 5
HER3 21 19 2
HER4 4 1 1
The expression of each member was measured by flow cytometric analysis
as described in the Materials and Methods. Each value represents the
specific peak fluorescence intensity divided by the background peak
intensity.
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Figure 1 Growth inhibitory effects of ICI 182,780 (10–9–10–7 M) in ML-20
cells (A), and those of rhumAbHER2 (0.1–10 mg ml–1) in ML-20 cells (B) and
in KPL-4 cells (C). The cells were incubated with medium containing the
reagents for 4 days and counted with a Coulter counter. The values
represent the percentages of the control and means of triplicate samples.
Bars, SE. *P < 0.05 in comparison with the control. **P < 0.01 in comparison
with the controlAdditive effect of rhuMAbHER2 and ICI 182,780 49
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significant increase was noted with their combination (P = 0.018
in comparison with the control, Table 3). In KPL-4 cells,
rhumAbHER2 alone slightly increased the percentage of TUNEL-
positive cells (Table 3). In the immunocytochemical analysis, both
ICI 182,780 and rhumAbHER2 significantly induced apoptosis
(P = 0.0001 and P = 0.0048 respectively) in ML-20 cells. The
combined treatment also induced apoptosis more than the respec-
tive agent alone (Table 3). In KPL-4 cells, rhumAbHER2 alone
significantly induced apoptosis (P = 0.0001, Table 3), but no
additive effect of the two agents on apoptosis was observed in
KPL-4 cells.
A small difference was observed between the two apoptosis
analyses in the percentages of apoptotic cells. The percentages in
the flow cytometric analysis tended to be higher than those in the
immunocytochemical analysis. These findings suggest the possi-
bility that the immunocytochemical analysis is more specific in
detecting apoptotic cells than the flow cytometric analysis.
DISCUSSION
Antioestrogen resistance frequently occurs in hormone-dependent
breast cancer following successful treatment with anti-oestrogen.
It has been demonstrated that HER2-overexpressing MCF-7 cells
which were transfected with a full-length of HER2 cDNA were no
longer sensitive to the anti-oestrogen tamoxifen (Benz el al, 1992).
Thus, it has been speculated that HER2 overexpression may be
one of the causes of anti-oestrogen resistance in human breast
cancer.
Previous reports have suggested a direct interaction between ER
and HER2-signalling pathways. It has been demonstrated that
oestrogen down-regulates HER2 expression and anti-oestrogen
partly reverses this oestrogen-induced HER2 down-regulation
(Read et al, 1990). Overexpression of a ligand for HER3 or HER4,
heregulin, which also stimulates the HER2-signalling pathway,
down-regulates ER-mediated transcription (Tang et al, 1996). Our
preliminary data on the regulation of HER2 expression by various
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Figure 2 Growth inhibitory effects of ICI 182,780 alone, 10 mg ml–1
rhumAbHER2 alone or their combination in ML-20 cells (A), KPL-4 cells (B)
or MDA-MB-231 cells (C). The cells were incubated with medium containing
the reagents for 4 days and counted with a Coulter counter. The values
represent the percentages of the control and means of triplicate samples.
Bars, s.e.m. *P < 0.05 in comparison with the control. **P < 0.01 in
comparison with the control
Table 2 Effects of ICI 182,780 alone, rhumAbHER2 alone or their
combination on cell cycle progression in ML-20 and KPL-4 human breast
cancer cell lines
Cell line Treatment % S % G0/G1
ML-20 Control 16.7 ± 0.3 75.6 ± 0.2
ICI 182,780 7.9 ± 1.1b 85.3 ± 1.4b
rhumAbHER2 13.7 ± 1.3b 78.4 ± 0.7a
Combination 6.3 ± 0.4b 86.6 ± 0.2b
KPL-4 Control 25.8 ± 0.5 60.9 ± 0.6
ICI 182,780 27.8 ± 1.2 59.2 ± 1.0
rhumAbHER2 23.8 ± 0.8 62.4 ± 1.4
Combination 24.8 ± 1.3 62.1 ± 2.1
10–7 M ICI 182,780 alone, 10 mg ml–1 rhumAbHER2 alone or their combination
was added to the culture medium and the cells were incubated for 3 days.
Percentages of the S phase and G0/G1 of the cell cycle were measured by
flow cytometric analysis as described in the Materials and Methods. The
values represent means ± s.e.m. of triplicate samples. aP < 0.05 in
comparison with the control. bP < 0.01 in comparison with the control.
Table 3 Effects of ICI 182,780 alone, rhumAbHER2 alone or their
combination on apoptosis measured by flow cytometric or
immunocytochemical analysis in ML-20 and KPL-4 human breast cancer cell
lines
Assay method Treatment Cell line
ML-20 KPL-4
Flow cytometry Control 4.9 ± 1.0 4.2 ± 0.7
ICI 182,780 8.7 ± 2.6 4.2 ± 0.2
rhumAbHER2 6.4 ± 0.0 4.9 ± 1.1
Combination 10.5 ± 0.7a 4.4 ± 0.9
Immunocytochemistry
Control 1.0 ± 0.5 2.7 ± 0.2
ICI 182,780 4.3 ± 0.8b 2.9 ± 0.9
rhumAbHER2 2.9 ± 1.0b 5.0 ± 0.4b
Combination 7.5 ± 1.5b 4.7 ± 0.6b
10–7 M ICI 182,780 alone, 10 mg ml–1 rhumAbHER2 alone or their combination
was added to the culture medium and the cells were incubated for 2 days.
Percentages of apoptotic cells were measured by flow cytometric or
immunocytochemical analysis as described in the Materials and Methods.
The values represent means ± s.e.m. of triplicate samples. aP < 0.05 in
comparison with the control. bP < 0.01 in comparison with the control.50 H Kunisue et al
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hormones in breast cancer cells also suggest that oestrogen down-
regulates HER2 expression and anti-oestrogen up-regulates it
(unpublished data). In addition, a recent clinical report suggested
that an anti-oestrogen, tamoxifen, improves the outcome of
patients with breast cancer without HER2-overexpression, while
showing a paradoxical detrimental effect in patients with HER2-
positive breast cancer (Bianco et al, 1998). These findings suggest
that anti-oestrogen may promote breast cancer cell growth through
the HER2-signalling pathway in ER- and HER2-positive breast
cancer and prompted us to investigate a possible additive effect of
anti-oestrogen and a blocker of HER2-signalling pathway, anti-
HER2 antibody, in breast cancer cells.
It has been suggested that concomitant treatment with an anti-
oestrogen, tamoxifen, and a murine monoclonal anti-HER2 anti-
body, 4D5, enhanced the anti-proliferative activity in ER- and
HER2-positive BT474 breast cancer cells (Witters et al, 1997).
In contrast, results of another experiment indicated that
rhumAbHER2, which was used in the present study and a human-
ized form of 4D5, has no growth-inhibitory effect on MCF-7 cells
(Lewis et al, 1993). The ML-20 cell line used in the present study
is a transfectant of the MCF-7 cell line with a bacterial lacZ gene
and its growth characteristics in vitro and in vivo are indistinguish-
able from the wild-type MCF-7 cell line (McLeskey et al, 1998).
We confirmed that ML-20 cells express a high level of ER
and a moderate level of HER2 (Table 1). rhumAbHER2 alone
(0.1–10 mg ml–1) dose-dependently inhibited the growth of ML-20
cells (Figure 1). The discrepancy in the effects of this antibody
may be explained as follows. The phenol red-free medium supple-
mented with dextran-coated charcoal FBS used in the present
study contains less endogenous oestrogen than the medium which
was used in the other study. The lower level of oestrogen in our
medium may induce HER2 expression in ML-20 cells and may
enhance the growth inhibitory effect of rhumAbHER2.
To explore the mechanisms responsible for the growth
inhibitory effect of ICI 182,780 and rhumAbHER2, their influ-
ences on cell cycle progression and apoptosis were investigated. It
has been reported that anti-oestrogen causes a G1–S blockade and
induces apoptosis in ER-positive breast cancer cells (Perry et al,
1995; Watts et al, 1995). It is also suggested that a murine anti-
HER2 antibody induces apoptosis in HER2-overexpressing cancer
cells (Kita et al, 1996). In the present study, ICI 182,780 signifi-
cantly induced a G1–S blockade and apoptosis in ER-positive
ML-20 cells but not in ER-negative KPL-4 cells. rhumAbHER2
also significantly induced a G1–S blockade and apoptosis in
ML-20 cells, which express a moderate level of HER2, but not in
MDA-MB-231 cells, which express a low level of HER2. In
KPL-4 cells, rhumAbHER2 caused a significant induction of
apoptosis and a slight G1–S blockade. Interestingly, the combined
treatment with ICI 182,780 and rhumAbHER2 enhanced the
induction of either a G1–S blockade or apoptosis in ML-20 cells
which express both ER and HER2 (Tables 2 and 3). These findings
in the present study support the findings in previous reports indi-
cating that either ICI 182,780 alone or rhumAbHER2 alone causes
a G1–S blockade and apoptosis in breast cancer cells and this
results in the retardation of cell growth.
Combined treatment with rhumAbHER2 and a certain cytotoxic
agent, such as cisplatin, paclitaxel or doxorubicin/cyclophos-
phamide, has been reported to be a promising approach for the
treatment of advanced breast cancer (Pegram et al, 1998; Slamon
et al, 1998). However, the action mechanisms responsible for their
additive effect remain to be elucidated. In addition, an unexpected
adverse effect of their combination; that is, cardiotoxicity, has
been reported (Slamon et al, 1998). rhumAbHER2 may also
enhance the anti-tumour effect of hormonal agents, such as anti-
oestrogen, as indicated in this study. Thus, it is conceivable that
combined treatment with a HER2-signalling blocker and a
hormonal agent might be a new promising therapeutic approach
for ER- and HER2-positive breast cancer.
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